OncoZenge AB
3.30
SEK
-0.05
(-1.64%)
OncoZenge AB
STO:ONCOZ
(Nasdaq Stockholm)
Recent
price
3.30
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.- Similar Companies
- Business
- OncoZenge AB (publ) (ONCOZ.ST) develops and commercializes innovative oral mucoadhesive buccal tablets and lozenges designed to deliver drugs directly through the oral mucosa, targeting unmet needs in supportive cancer care and other therapeutic areas. The company's core products include the OncoZenge platform technology, which enables rapid onset of action and improved bioavailability for small molecules; its lead product candidate ONZEDRA (previously referred to as OZ-Breast), a buccal tablet for preventing and treating oral mucositis in cancer patients undergoing chemotherapy or radiotherapy; and a pipeline of additional formulations for nausea, dry mouth, and pain management in oncology settings. These products leverage mucoadhesive polymers to adhere to the buccal mucosa, bypassing first-pass metabolism for faster relief compared to traditional oral dosage forms. Founded in 2018 and headquartered in Lund, Sweden, OncoZenge operates primarily in the European Union with clinical trials and regulatory activities focused on the Nordic region and broader EU markets, serving pharmaceutical partners, hospitals, and oncology clinics as target customers. The company functions within the biopharmaceutical industry, specifically the oncology supportive care segment, and maintains a lean structure as a publicly listed entity on Nasdaq First North Growth Market. In recent developments, OncoZenge completed a rights issue in Q3 2025 raising approximately SEK 25 million to fund the ongoing Phase 3 trial for ONZEDRA, which achieved positive topline results in October 2025 demonstrating statistically significant reduction in severe oral mucositis incidence. The company entered a strategic manufacturing partnership with Recipharm AB in early 2025 to scale up production for commercialization expected in 2026, and expanded its pipeline with a new licensing agreement for a dry mouth treatment candidate in September 2025. These milestones position OncoZenge for regulatory submission to the European Medicines Agency in H1 2026, marking a shift toward late-stage clinical validation and market entry.